CD274 and neoplasm: The predictive value of tumor PD-L1 expression and mutational burden (TMB), which are used as companion diagnostic biomarkers for other tumor types, remains equivocal in RCC, with a number of studies demonstrating no correlation with response [2,3,6,7,9,10,11].